Incorrect to Eliminate Portions of A Mark and Then Compare
Client Alert | 1 min read | 06.25.07
In China Healthways Institute, Inc. v. Wang (No. 2006-1464; June 22, 2007), the Federal Circuit reverses the Trademark Trial and Appeal Board’s denial of Chi Institute’s opposition to the registration of the mark CHI PLUS by Wang for “electric massage apparatus.” Chi Institute makes and sells electric therapeutic massagers under the trademark CHI (Stylized).
Chi Institute filed an opposition on the grounds that there is a likelihood of confusion as the two marks are similar. The Board held that there was no likelihood of confusion even though the goods are legally identical and move in the same channels of trade to the same class of consumers. In so holding, the Board concluded that CHI is a weak component of the marks and is at the least, very highly suggestive, if not merely descriptive when used in connection with the intended goods.
The Court disagrees finding that “the word CHI is a significant component of these marks when viewed in their entirety” and must be given appropriate weight. The Court holds that it is “incorrect to compare marks by eliminating portions thereof and then simply comparing the residue.” The Court concludes that the similarities of the two marks are so strong as to be likely to lead consumers to believe that the products they are purchasing come from the same source.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
